AUG 11, 2026 · JOURNAL ARTICLE
Smyca-FOXM1 ribonucleoprotein complex promotes homologous recombination and tumor immune evasion to define a therapeutic target of triple-negative breast cancer
Journal of Biomedical Science
Mechanistic discovery study using cell assays, organoid and mouse models identifying Smyca-FOXM1 as a potential target, without clinical trial data or hard clinical outcomes to support therapeutic claims.
Study details
DesignMechanistic and preclinical study using in…
InterventionSmyca ablation, targeting of Smyca-FOXM1 co…
ComparatorControl (non-targeted or vehicle-treated) m…